Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Successfully Doses First Patient with CYAD-02 in CYCLE-1 Trial for r/r AML and MDS

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Presents Update on r/r AML and MDS Program at 61st ASH Annual Meeting

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

Celyad Receives Additional €2.5 Million in Non-Dilutive Funding

Celyad Announces Board of Directors Evolution with New Appointment

Celyad Announces Board of Directors Evolution with New Appointment

Discover our news

Upcoming events

Discover all events

a

Press contacts

Celyad

Alexandrine Hazard, Communications Associate

+32 (0)10 39 41 58

LifeSci Advisors

Sara Zelkovic

Ulysse Communication (Europe)

Bruno Arabian